# Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

> **NCT01370694** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 7 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** MK-8808
- **DRUG:** cyclophosphamide
- **DRUG:** vincristine
- **DRUG:** prednisolone

## Key facts

- **NCT ID:** NCT01370694
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08-19
- **Primary completion:** 2014-12-01
- **Final completion:** 2014-12-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study was terminated for business reasons.
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01370694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01370694, "Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01370694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*